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ABSTRACT
The integration of high-throughput genomic
data represents an opportunity for deciphering the
interplay between structural and functional organi-
zation of genomes and for discovering novel bio-
markers. However, the development of integrative
approaches to complement gene expression (GE)
data with other types of gene information, such as
copy number (CN) and chromosomal localization,
still represents a computational challenge in the
genomic arena. This work presents a computational
procedure that directly integrates CN and GE pro-
files at genome-wide level. When applied to DNA/
RNA paired data, this approach leads to the identi-
fication of Significant Overlaps of Differentially
Expressed and Genomic Imbalanced Regions
(SODEGIR). This goal is accomplished in three
steps. The first step extends to CN a method for
detecting regional imbalances in GE. The second
part provides the integration of CN and GE data
and identifies chromosomal regions with concor-
dantly altered genomic and transcriptional status
in a tumor sample. The last step elevates the
single-sample analysis to an entire dataset of
tumor specimens. When applied to study chromo-
somal aberrations in a collection of astrocytoma
and renal carcinoma samples, the procedure
proved to be effective in identifying discrete
chromosomal regions of coordinated CN alterations
and changes in transcriptional levels.
INTRODUCTION
Most tumor cells are characterized by genomics altera-
tions, as polyploidies, imbalances of entire chromosomes
and regional amplifications/deletions, which reflect in
changes of the DNA copy number (CN) status (1,2).
Another genomic aberration typical of tumors is loss of
heterozygosity (LOH), i.e. the change from a heterozygous
genotype in a normal sample to a homozygous one in a
tumor specimen. LOH is due to hemizygous deletion or
mitotic recombination and thus can occur with or without
associated changes of the CN status (3). The presence of
altered DNA CN and LOH may confer growth advan-
tages to cells, which will be selected in descendant cells
and contribute to cancer formation. Therefore, the pattern
of genomic modifications in a tumor represents a struc-
tural fingerprint that may influence the transcriptional
control mechanisms and locally impact the gene expres-
sion (GE) levels.
Several studies evidenced that, in tumors, there is a cor-
relation between CN and average global expression levels
of genes contained in the imbalanced chromosomal
region. In their pioneering study, Phillips and coworkers
(4) showed that the acquisition of tumorigenicity of an
immortalized prostate epithelial cell line resulted in chro-
mosomal gains and losses statistically correlated with
increase and decrease in the average expression level of
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involved genes. In particular, 51% of up-regulated genes
mapped to regions of DNA gain and 42% of down-
regulated genes mapped to chromosomal areas of DNA
loss. The findings from Phillips et al. were confirmed by
the study of Pollack (5) who provided further evidences
that widespread DNA CN alteration can lead directly to
a global deregulation of GE. In particular, Pollack et al.
reported that, in breast tumors and cell lines, DNA CN
influences GE across a wide range of DNA CN altera-
tions, with 62% of highly amplified genes showing mod-
erately or highly elevated expression. These observations
were further confirmed by Hyman (6) who illustrated
a considerable influence of CN on GE patterns.
Similar results were later reported in several other tumor
types (7–12).
In all of these studies, CN data have been obtained
using array-CGH (aCGH) technology. The integration
of expression and aCGH data is relatively straightfor-
ward, since genes are directly interrogated by specific
gene probes and the gene CN is readily available for the
same entity interrogated by the expression array. On the
contrary, using high-density single nucleotide polymorph-
ism (SNP) arrays, the CN value refers to a SNP marker
and the gene CN must be estimated. To date, only two
computational procedures have been developed to calcu-
late the gene CN directly from SNP mapping data
(i.e. FASeg and dChip) and none directly integrates gene
CN data with GE levels.
Linear regression models and statistical analysis of the
correlation coefficients between DNA CN and mRNA
expression data are normally used to estimate the fraction
of all variations measured in mRNA levels that could be
attributed to underlying changes in the DNA CN.
However, the relationship between CN imbalances and
GE changes in the complex genomic environment of a
tumor cell may not be effectively captured by the simple,
direct correlation of the signal levels. Since gains/losses in
the DNA CN may not directly translate to the same quan-
tity of expression change, computational approaches for
the integrative analysis of gene dosage and expression data
are needed for deciphering how the structural organiza-
tion of genomes influences their functional utilization.
This integrative approach is exemplified by the study of
Garraway and colleagues (13), in which the analysis of CN
data obtained by SNP mapping arrays drives the investi-
gation of pre-existing GE profiles. Specifically, CN data
were used to organize cancer samples into subgroups char-
acterized by specific chromosomal aberrations associated
to contiguous SNP chromosomal clusters. This genomic-
based sub-grouping constituted the new phenotypic label-
ing of the samples in the GE analysis, i.e. the NCI60
tissues were re-grouped into two new classes based on
the presence or absence of the amplification at chromo-
some 3p14–p13 before performing the supervised analysis.
The differential expression profiles, inside the SNP cluster
characterizing the CN amplification at 3p14–p13, revealed
the presence of a novel melanoma-specific oncogene.
Integrated analytical approaches to identify chromosomal
regions with significant co-occurrences of genomic imbal-
ances and differential expression may thus represent an
opportunity for upgrading the information content of
genomic data and for discovering novel cancer
biomarkers.
The purpose of this work is to present a bioinformatics
procedure that allows the integration of CN, obtained
from SNP mapping arrays, with transcriptional data, the
identification of genome-wide, concurrent alterations of
CN and regional GE in single tumor samples, and the
extension of the integrative analysis to entire cancer data-
sets. These two issues are achieved in three steps, i.e. (i) the
statistical estimation of CN and transcriptional scores
at common gene positions from microarray probe-data;
(ii) the identification of sets of consecutive genes
along the genome characterized by an unusually large
number of concurrently altered CN and GE across a
single-sample (thereof called Significant Overlap of
Differentially Expressed and Genomic Imbalanced
Regions, SODEGIR); and (iii) the aggregation of
SODEGIRs from different samples to obtain global sig-
natures of tumor types. The first step extends the Locally
Adaptive Statistical procedure [LAP, (14)] to SNP CN
data and detects regional alterations of CN at gene level
[Lokern Smoothing Copy Number (LSCN)]. The second
part provides the integration of CN and GE data statisti-
cally assessing gene dosage and transcriptional statuses on
common genomic positions (e.g. Entrez Gene IDs) and
identifies the SODEGIRs. The last step combines the var-
ious single-sample SODEGIRs into a unique, cancer spe-
cific SODEGIR signature. The whole methodology was
applied to SNP mapping and GE data obtained by
Affymetrix arrays from normal samples (Affymetrix refer-
ence), a renal cancer cell line (Caki-1), astrocytoma sam-
ples (15), and clear cell renal carcinoma samples (16). All
results are available at the Companion Web Site (CWS)
http://www.xlab.unimo.it/SODEGIR.
MATERIALS AND METHODS
Genome wide microarray technology and array datasets
CN and GE data have been obtained from public
microarray repositories and are fully described in
Supplementary Data. Briefly, the datasets comprise
Caki-1 (a tumor cell line and reference RNA samples),
Astro (a collection of astrocytoma specimens), RCC
(tissue samples from renal carcinoma patients) and refer-
ence DNA (AffyRef, normal individuals), for a total of
263 Affymetrix Human Mapping SNP and 66 GeneChip
HG-U133 Plus 2.0 arrays. Simulated data have been gen-
erated to test the performances of all computational steps,
as described in Supplementary Data.
Gene expression, CN and LOH data processing
GE values have been quantified using robust multi-array
average procedure [RMA, (17)] starting from .CEL files.
Chromosome Copy Number Analysis Tool 4.01 (CNAT
4.01, Affymetrix, 2007) and Copy Number Analyzer for
GeneChip 2.0 (CNAG 2.0) (18) were used to calculate
SNP CN and LOH profiles from mapping arrays
(Supplementary Table 1). The forward–backward
Fragment Assembling Segmentation algorithm (FASeg)
(19) was used to quantify gene CN from CNAT 4.01
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SNP CN data, as described in the Supplementary Data.
In all datasets, CN and LOH were determined through an
un-paired analysis using HapMap samples as normal gen-
otype reference. In addition, a paired analysis was carried
out to quantify CN and LOH for the RCC dataset (RCCp)
where pairs of tumor tissue and blood samples were
available.
The SODEGIR method
The SODEGIR method is a three-step bioinformatics pro-
cedure for the identification of genome-wide, concomitant
alterations of CN and GE in single samples and in com-
plete datasets (Figure 1 and Supplementary Data). The
first step stems from the Locally Adaptive Statistical pro-
cedure (LAP) (14), a statistical approach for the identifi-
cation of imbalances in regional GE. LAP is here extended
to SNP CN data, with the aim to detect alterations of
regional CN at gene level. The second part statistically
assesses the CN and GE statuses on common genomic
positions (e.g. Entrez Gene IDs) and identifies the
SODEGIRs, i.e. those chromosomal regions where the
CN and GE statuses are concordant at a given statistical
threshold, in a single sample. In the last step, the various
single-sample SODEGIRs are statistically combined to
assess a unique SODEGIR signature for an entire dataset.
The entire procedure is coded in a set of R functions which
are available in the CWS along with documentation and
sample data.
Step 1. The first step transforms SNP CN and expression
data into CN and GE scores and integrates them with
structural information (i.e. chromosomal coordinates),
using a kernel regression estimator with an adaptive band-
width. Resembling LAP (14), the kernel smoothing
allows estimating CN and GE scores at the chromosomal
locations of Entrez Gene IDs from the probe set data of
the microarrays. This first step can be applied separately
to SNP CN and GE data. In the former case, the proce-
dure is named LSCN, while the latter represents a revised
version of LAP.
CN score. In the LSCN part of the procedure, CN data
are transformed into a score NSNPi,j which quantifies, for
each SNP i in any sample j, the amplitude of the CN
variation from the diploid status. Since several evidences
questioned the assumption that normal samples have
CN equal to 2 everywhere (20,21), the CN value of the
diploid status is not set to 2 (i.e. log2 ratio=0), but is
estimated from the median CN calculated over all i SNP
probes (i=1, . . . ,L) of the array. As such, the CN score
NSNPi,j can be defined as follows:
NSNPi,j ¼ NSNPi,j min ~NSNPj ,thrN
 
1
where NSNPi,j is the CN of SNP i in sample j,
~NSNPj is the
median CN calculated over all the i SNP probes of array
j and thrN=0.05 is a control threshold to cope with
potential outlying samples (see Supplementary Data).
GE score. In its original version, LAP calculates a statistic
for ranking probes in order of strength of differential
expression in two or more populations (14). Here, con-
sidering a single sample j from a population of m patho-
logical samples with normalized expression level xi,j for
probe set i (i=1, . . . ,P) and a population of n normal
specimens with average GE xnormi , the GE score E
probe
i,j
can be defined as
E
probe
i,j ¼
xi,j  xnormi
si þ s0 , 2
where the standard deviation si for each probe set i
is estimated using all pathological and normal samples
and is stabilized by the factor s0 as in SAM (22):
si ¼ a
Xm
j¼1
xi,j  xpatoli
 2
þ
Xn
k¼1
xi,k  xnormi
 2" #( )1=2
a ¼ mþ n
m  n 
1
mþ n 2
3
Estimation of scores at gene positions: lokern
smoothing. CN and GE scores are estimated at gene posi-
tions integrating probe set data and structural information
using a kernel regression estimator with an automatically
adapted local plug-in bandwidth. Specifically, CN and
GE values are estimated at the same gene physical posi-
tion from the signals of SNP and transcripts probes. As
described in ref. (14,23), the integration of variational
scores and structural information corresponds to estimate
the value of a score at a given chromosomal coordinate,
e.g. the Entrez Gene physical position of a gene in
base pairs. This integration can be formally stated as a
non-parametric regression problem where the score is to
be estimated over fixed chromosomal coordinates using a
smoothing function. In this particular case, CN and GE
scores are integrated with structural information using
the lokern functions, a set of kernel regression estimators
with adaptive smoothing bandwidth (24). Specifically,
for each sample j, the regression model specifies:
NSNPi,j ¼ j Mbið Þ þ i,j
E
probe
i,j ¼ j Mbið Þ þ "i,j
4
where Mbi is the physical position of SNP (probe) i,
j(Mbi) and j(Mbi) are arbitrary functions of Mbi, and
i,j and "i,j are independent and identically distributed
(i.i.d.) errors with zero mean. In these non-parametric
models, the systematic part of the variation, i.e. the depen-
dence of NSNPi,j (E
probe
i,j ) on the physical position Mbi,
is left as an arbitrary function j(Mbi) [or j(Mbi)], while
the random part is specified by assuming that the error
components are uncorrelated with zero mean and constant
variance. Considering for instance CN values, the regres-
sion model takes as input the pairs (Mbi,N
SNP
i,j with
i=1, . . . ,L), estimates EðNSNPi,j Þ ¼ j Mbið Þ by extracting
a curve from the data, and returns the values Ngeneg,j of
j (Mbg) at given design points Mbg (e.g. the g physical
position of Entrez Genes).
Thus, the lokern functions take as input a vector
of NSNPi,j and/or E
probe
i,j scores ordered with respect to
a vector of i spatial coordinates (i.e. the physical positions
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of SNP/transcript probes in the mapping/GE array)
and return as output the scores Ngeneg,j and/or E
gene
g,j esti-
mated at the g physical position of G=16395 annotated
Entrez Genes. The adaptive smoothing bandwidth
accounts for the non-uniform distribution and density of
genes along the genome and the smoothing function per-
forms a local averaging of the observations when estimat-
ing the regression function. The lokern package contains
functions that calculate the regression with an automati-
cally chosen local (lokerns) or global (glkerns) bandwidth.
Step 2. In the second step, the goal is to assess the statis-
tical significance of CN and GE variations and to define
regions with concomitant alterations of gene CN and GE
in single samples. The procedure locally computes the sta-
tistical confidence levels (i.e. p- and q-values) through a
permutation scheme and estimates the CN and GE sta-
tuses of annotated genes. Finally, SODEGIRs are defined
based on the CN and transcriptional statuses.
Assessment of statistical significance. A permutation
scheme is used to identify chromosomal regions with
statistically significant CN and GE imbalances under the
assumption that each chromosomal position has a unique
neighborhood and that the corresponding score is not
comparable with any score in other regions of the
genome (14). Assuming no difference between chromo-
somal positions, all scores can be considered from the
same population and an empirical distribution of the
test statistic under the null hypothesis can be constructed
randomly assigning the scores to the chromosomal loca-
tions. Specifically, the scope is to make inferences about
j(Mbg) [or j(Mbg)] at each position g by testing the
significance of a departure from the null form of j(Mbg)
[or j(Mbg)] corresponding to no alterations of CN (GE).
This corresponds to test the following multiple hypoth-
eses, for CN and GE, respectively:
HNg,j : j Mbg
  ¼ 0
KNg,j : j Mbg
  6¼ 0 g ¼ 1, . . . ,G and
HEg,j : j Mbg
  ¼ 0
KEg,j : j Mbg
  6¼ 0 g ¼ 1, . . . ,G
5
When no alterations of CN (GE) are present along the
genome, i.e. when
TG
g¼1H
N
g,j (
TG
g¼1H
E
g,j) is true, the
observed data values NSNPi,j ¼ i,j (Nprobei,j ¼ "i,j) are
i.i.d. realizations and thus are exchangeable:
NSNP1 , . . . ,N
SNP
L
 ¼d NSNP 1ð Þ , . . . ,NSNP Lð Þ 
E
probe
1 , . . . ,E
probe
P
 
¼d Eprobe 1ð Þ , . . . ,Eprobe Pð Þ
  6
where {(1),. . .,(L)} and {(1),. . .,(P)} represent arbi-
trary permutations of {1,. . .,L} and {1,. . .,P}, respectively
and ¼d denotes equality in distribution. This implies
that, starting from the original data, all L! (P!) permuta-
tions of the data are equally likely and that a
permutation scheme can be used to identify chromosomal
regions with statistically significant CN and GE imbal-
ances. Specifically, at each permutation, NSNPi,j and
E
probe
i,j scores are randomly assigned to chromosomal
locations and Ngeneg,j and E
gene
g,j re-estimated using the
lokerns function (permuted scores Ngene,bg,j and E
gene,b
g,j ).
The permutation process, over B random assignments,
defines the distribution of the null scores for any output
design position. Since the observed and expected gene CN
and GE scores are estimated using the same function over
the same input and output design points, the significance
of CN and transcriptional imbalances can be computed
testing HNg,j and H
E
g,j on the estimated scores N
gene
g,j and
Egeneg,j as test statistic, respectively. The significance p
N
g,j
(or pEg,j) that the expected score N
gene,b
g,j (or E
gene,b
g,j )
exceeds the observed one Ngeneg,j (or E
gene
g,j ), over B
permutations, can be then computed as follows:
pNg,j ¼
PB
b¼1
I Ngene,bg,j
   Ngeneg,j n o
B
pEg,j ¼
PB
b¼1
I Egene,bg,j
   Egeneg,j n o
B
7
where I{} is an indicator function that takes the value 1
if the argument is true and 0 otherwise.
These p-values pNg,j and p
E
g,j have the peculiarity to be
local, since the observed scores are compared only with
the expected ones estimated on the same neighborhood of
gene position g. Indeed, during the permutation process,
the chromosomal position is conserved while the scores
are randomly shuffled. Once the distributions of empirical
p-values have been generated, the q-value is used to
correct the measure of significance for multiple testing.
Status quantification and SODEGIR definition. When the
null hypothesis HNg,j (H
E
g,j) is rejected, the CN (or GE)
status of a gene g in a sample j is decided basing on
whether j(Mbg) [or j(Mbg)] is smaller or greater than
zero. The two-sided hypotheses of Equation (5) are equiv-
alent to the simultaneous testing of the following pair
of one-sided hypotheses:
HNgaing,j : j Mbg
   0 against KNlossg,j : j Mbg  < 0
HNlossg,j : j Mbg
   0 against KNgaing,j : j Mbg  > 0
H
Eup
g,j : j Mbg
   0 against KEdowng,j : j Mbg  < 0 and
HEdowng,j : j Mbg
   0 against KEupg,j : j Mbg  > 0
8
Considering for instance CN, the rejection of either HNgaing,j
or HNlossg,j is equivalent to the rejection of H
N
g,j. Although
Equations (5) and (8) are equivalent ways of formulating
the same hypothesis testing problem, there is some advan-
tage in using the formulation of Equation (8). Indeed,
when the action to take in the event of rejection of HNg,j
(or of HEg,j) depends upon which tail brought about the
rejection, KNlossg,j or K
Ngain
g,j (and K
Edown
g,j or K
Eup
g,j ) can be
associated with the two courses of action.
In particular, the null hypothesis HNg,j (H
E
g,j) is rejected
according to thresholds on the q-value and on the scores.
The q-value and score thresholds for CN and GE may be
set to different values, depending on the desired stringency
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of the analysis (Supplementary Data). The CN q-value
and score thresholds have been optimized based on the
analysis of the AffyRef Reference DNA dataset, Egeneg,j
thresholds have been selected according to the criteria
used for the CN ones, and GE q-value threshold has
been set to the value commonly used with GE data (14).
CN and GE statuses are coded as 1 (CN loss, GE down-
regulation) when the q-value is below the q-value thresh-
old (e.g. 0 or 0.05) and the score is smaller than the
low score threshold (e.g. the 10th quantile of scores), 3
(CN gain, GE up-regulation) when the q-value is below
the q-value threshold and the score is larger than the high
score threshold (e.g. the 90th quantile of scores,
Supplementary Table 2), and 2 (CN and GE neutral) in
all other cases. Given the quantification of CN and GE
statuses in a single sample, a SODEGIR corresponds to a
region of the genome where the CN and GE statuses are
concordant (see Supplementary Data for details on the
hypothesis intersection-union formulation). In particular,
if both CN and GE statuses are equal to 1, the SODEGIR
indicates deletion (SODEGIR status 1), while, if CN and
GE statuses are both 3, the SODEGIR indicates amplifi-
cation (SODEGIR status 3).
Step 3. The third step provides a statistical method
to elevate the analysis from the single to the multiple-
sample level and to detect the presence of a common
SODEGIR signature across an entire dataset. In details,
let Sg,j be the SODEGIR status for sample j at the gene g
and assume that Sg,j follows a multinomial distribution
with Pr Sg,j ¼ 1
  ¼ 1g, Pr Sg,j ¼ 2  ¼ 2g, Pr Sg,j ¼ 3 ¼ 3g and 1g þ 2g þ 3g ¼ 1. Under the null hypothesis
that there are no real imbalanced regions, these proba-
bilities are independent from g, i.e. sg ¼ s, s ¼ 1,2,3.
Then for each gene g, the following hypotheses are tested:
H1g : 
1
g ¼ 1 against K1g : 1g > 1
H3g : 
3
g ¼ 3 against K3g : 3g > 3
9
When there are no real imbalanced regions, i.e.
when
TG
g¼1H
s
g is true, a reasonable estimator of 
s is
given by ^s¼
PJ
j¼1
PG
g¼1 I Sg,j¼sf g

=

GJ

: The test statistic
Tg¼
PJ
j¼1 I Sg,j¼sf g, which is distributed as Binomial(J,s)
when Hsg is true, can be used to test eachH
s
g. Hence,
the p-value is given by
psg ¼ Pr Tg  tg
  ¼XJ
r¼tg
J
r
 
^s
 r
1 ^s
 Jr
, 10
where tg is the observed frequency of SODEGIR status s
at gene g across the J samples.
Once computed the p-values for each gene, the q-value
is used to assign a measure of significance to each of the
many tests simultaneously performed and is adopted as a
summary score for deletions or amplifications.
RESULTS
The SODEGIR procedure (Figure 1) has been optimized
and tested on CN and GE data obtained using Affymetrix
Human Mapping 100K or 250K and HG-U133 Plus 2.0
arrays, respectively. In particular, the datasets comprise
normal samples (DNA Affymetrix reference, AffyRef,
http://www.affymetrix.com/support/datasets.affx), a renal
tumor cell line (Caki-1), a subset of 12 astrocytomas sam-
ples (Astro) obtained from a public dataset of gliomas (15)
and 12 clear cell renal carcinomas (RCCp and RCC) com-
bined in paired normal/tumor specimens (16). All samples
were firstly used to tune the parameters of the LSCN part
of the procedure, i.e. to define an appropriate CN score
and to verify the performances of the kernel-based estima-
tor in calculating gene CN values. Given its definition, the
CN score required to quantify the CN of the diploid
status. Since several evidences questioned the assumption
that normal samples have CN equal to 2 (20,21), the CN
value corresponding to the diploid status was not set to 2
(i.e. log2 ratio=0), but estimated directly from the data.
In particular, as shown in Supplementary Figure 2, the
median values of the various arrays, although not equal
to zero, are tightly distributed around zero (log2 ratio=0,
CN=2), irrespectively that the data represent normal
(AffyRef and Blood) or pathological samples (Astro,
RCCp and RCC). Given this evidence, the CN value of
the diploid status was quantified as the median CN calcu-
lated over all SNP probe sets of a mapping array.
The efficacy of the locally adaptive approach (i.e.
the lokerns function) in smoothing GE scores has been
already shown in ref. (14), while its performance with
GE scoreCN score
Mapping
arrays
Expression
arrays
log2signals
Genome
Annotations
assessment of
statistical significance
GE status
Single sample
SODEGIRs
data aggregation from
different tumors
Dataset
SODEGIR signature
CN status
kernel smoothing with
adaptive bandwidth
kernel smoothing with
adaptive bandwidth
assessment of
statistical significance
LSCN LAPlog2ratios
Figure 1. Workflow of SODEGIR procedure: (1) statistical estimation
of CN and transcriptional scores at common genomic positions;
(2) identification of significant overlap of differentially expressed and
genomic imbalanced regions (SODEGIR) on a single-sample basis; and
(3) aggregation of SODEGIRs from different samples to obtain global
signatures of tumor types.
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CN scores has been tested through the analysis of all
normal and tumor samples. In particular, lokerns esti-
mates CN scores at gene positions preserving the pattern
of CN scores of SNP probes (Supplementary Figure 3,
Panel A and CWS, AffyRef). Indeed, the estimated gene
CN scores of 16 395 annotated Entrez Gene IDs perfectly
reproduce SNP CN scores in CN neutral samples
(Supplementary Figure 3, Panel A, chromosome 11 in
AffyRef NA17203) and in samples presenting broad
gains and losses (Supplementary Figure 3, Panel B, chro-
mosome 7 in RCCp 27CG; Panel C, chromosome 10 in
Astro HF1232). Moreover, the lokerns function is able to
detect mixed patterns of CN changes as spikes and simul-
taneous loss and gain of chromosomal arms (Supplemen-
tary Figure 3, Panel D, chromosome 7 in Astro HF1232;
Panel E, chromosome 5 in RCCp 50PC; Panel F, chromo-
some 3 in RCCp 27CG). Finally, lokerns regresses effi-
ciently the CN score irrespectively of the array density
(50K, 100K and 250K sets), although denser arrays
allow a finer smoothing of the data using smaller band-
widths (Supplementary Figure 4). Thus, consistently with
the GE analysis by LAP, the locally adaptive approach
implemented by the lokerns function has been adopted
also for regressing CN scores.
Since the true status of genes is unknown in real data
sets, the performance of the proposed procedure was
assessed on synthetic data through a simulation analysis.
Differently from real data, in an artificial data set the true
status and the test result of each gene are known. Since
the processes generating GE and CN signals and their
underlying probability distributions in real datasets are
unknown, synthetic data have been generated directly
from the GE and CN values. Specifically, artificial CN
and GE data mimicking samples with no alterations
(gene status=2) have been obtained independently per-
muting CN and expression values within each chromo-
some c in each sample j derived from six out of 11
normal specimens of the RCC dataset (28RA, 33BV,
36MML, 37BA, 40RR and 50PC). Several random
data generations were used to verify the performances of
the entire procedure under the null hypothesis. To test the
performances of LSCN, LAP and SODEGIR under the
alternative hypothesis, CN and GE values of genes in a
non-neutral status were generated adding (or subtracting)
specific constants kN and kE to the data generated under
the null hypothesis. Specifically, the non-neutral status
of CN and GE signals has been simulated generating 10
non-neutral effects (named from A to L in Supplementary
Table 5), differing in terms of affected chromosome (e.g.
chromosomes 1 and 3), size of the affected regions (chro-
mosomal segments or entire arms), and amplitude of the
effect (small, medium, large) added or subtracted to CN
and GE data. Moreover, these 10 effects have been mixed
in two major scenarios, one named small regions and other
named large regions, composed of 10 configurations each.
In particular, the small regions scenario simulates matched
and un-matched CN and GE effects (i.e. the existence
or not of SODEGIRs) in relatively small chromosomal
regions, while the large regions scenario mimics amplifica-
tion or deletions of entire chromosomal arms (see
Supplementary Data for details on the generation of
synthetic data). The performances have been quantified
in terms of sensitivity=TP/(TP+FN), i.e. the proportion
of altered genes (true positives, TP) which are correctly
identified as such with respect to the total number of
altered genes (TP plus false negatives, FN), and of False
Discovery Rate, FDR=FP/(TP+FP), i.e. the propor-
tion of false positives (FP) among the genes identified as
altered (TP+FP). The analysis of the simulated data sets
and the quantification of the observed CN, GE and
SODEGIR statuses (according to the thresholds of
Supplementary Table 2) lead to a mean sensitivity of
0.91, 0.94 and 0.87 and a mean FDR of 0.014, 0.019
and 0.005 for LSCN, LAP and SODEGIR procedures,
respectively.
The entire SODEGIR procedure was then applied to
the various cancer data sets to identify single sample and
dataset signatures. All results, including chromosome and
genome views for single samples and for entire datasets, as
well as tables with the characteristics of all CN, GE and
SODEGIR regions, are available at CWS. The analysis of
the tumor cell line Caki-1 allowed the detection of more
than 26 SODEGIRs distributed over 11 chromosomes,
using the Mapping 100K CN data. In details, the Caki-1
sample contains about 470Mb of CN alterations, about
570Mb of regions affected by GE imbalances and 170Mb
of SODEGIRs (Table 1 and Caki100K.SDG_Table
Table 1. Impact of CN, GE and SODEGIR regions in terms of total
megabases (Mb) and percentage of the genome (%) for the various
tumor samples
Sample ID CN GE SODEGIR
Mb % Mb % Mb %
Caki dataset
Caki_100K 469.884 16 567.536 19 166.246 6
Caki_250K 488.047 16 567.536 19 172.702 6
Astro dataset
HF0017 190.089 6 67.354 2 30.451 1
HF0108 318.065 11 164.59 5 89.831 3
HF0152 185.689 6 218.398 7 44.591 1
HF0491 289.853 10 184.265 6 11.172 0
HF0608 180.63 6 356.129 12 42.516 1
HF1139 302.704 10 349.615 12 228.719 8
HF1232 380.549 13 301.414 10 217.409 7
HF1269 459.684 15 432.209 14 140.952 5
HF1344 382.209 13 393.79 13 262.443 9
HF1442 247.563 8 176.247 6 100.145 3
HF1469 100.576 3 67.683 2 1.784 0
HF1511 255.157 9 39.215 1 13.809 0
RCCp dataset
27CG 452.867 15 477.841 16 213.958 7
28RA 443.696 15 506.478 17 291.786 10
33BV 509.906 17 171.066 6 150.24 5
36MML 538.907 18 232.542 8 141.616 5
37BA 295.591 10 375.085 13 36.954 1
40RR 208.409 7 52.964 2 14.09 0
45DM 177.191 6 399.721 13 91.845 3
46SA 551.945 18 582.158 19 194.366 6
47CA 380.862 13 394.464 13 169.46 6
49CA 472.772 16 336.733 11 242.828 8
50PC 341.269 11 410.785 14 159.763 5
51MI 416.003 14 456.929 15 72.311 2
Values have been derived from .SDG_Table files of each sample, as
deposited in CWS.
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at CWS). Figure 2 displays the genome view of Caki-1
with the regions of CN gain/loss, GE up-/down-regulation
and deleted (CN loss and GE down-regulation) and ampli-
fied (CN gain and GE up-regulation) SODEGIRs. Broad
amplified and deleted SODEGIRs are localized on chro-
mosomes 1q, 3q, 4p, 10p and 17q and on chromosomes
3p, 14q and 21q, respectively. Regions of gene CN gain/
loss identified by LSCN are in close agreement with SNP
CN alterations evidenced by CNAG (see CWS). This evi-
dence is further detailed in Figure 2B where CN (N_AB)
and LOH statuses, as estimated by the CNAG HMM
on each SNP probe, are compared to CN, GE, and
SODEGIR statuses determined by the SODEGIR proce-
dure on gene positions of chromosome 3. It is worthwhile
noting that regions with CN loss may or may not be asso-
ciated to LOH. This is exemplified in chromosome 3,
where the lack of LOH in the deleted region suggests the
presence of aneuploidy, and in chromosome 14 of Caki-1
where the association of deletion and LOH indicates the
loss of diploidy. On the contrary, amplified SODEGIRs
are not usually associated to SNP LOH status (see CWS).
Interestingly, SODEGIRs represent regions where the
Figure 2. Visualization of SODEGIR results for the analysis of Caki-1 single sample using 100K mapping array. (A) Genome view: regions of CN
gain/loss, GE up-/down-regulation and deleted (CN loss and GE down-regulation) and amplified SODEGIRs (CN gain and GE up-regulation) are
shown as boxes on each chromosome. As in the cPlot view of R geneplotter package, horizontal lines represent chromosomes and grey bars indicate
gene positions. Three lines per chromosome and shades of red and green are used to display CN gain/loss, GE up-/down, and SODEGIRs amplified
and deleted. (B) Chromosome view of chromosome 3: CN status (N_AB) and LOH status as estimated by the CNAG HMM on each SNP probe,
CN, GE and SODEGIR statuses as determined by the SODEGIR procedure on gene positions for a given chromosome in a single sample. The grey
bars indicate SNP probes (in N_AB and LOH lanes) or Entrez Gene ID positions (for CN, GE and SODEGIR lanes). Red and green bars in the
N_AB lane indicate N_AB >3 and <1, respectively. Blue bars in the LOH lane highlight SNP probes with an inferred LOH value >20. Green bars in
CN, GE, and SODEGIR lanes indicate loss, down-, or deletion (i.e. a status of 1). Red bars in CN, GE, and SODEGIR lanes indicate gain, up-, or
amplification (i.e. a status of 3). (C) Genome boxplot: distribution of gene GE scores according to gene CN scores on all SODEGIRs of the entire
genome. CN levels are categorized into five bins highlighting two ranges of loss (green boxes, gene CN score <0.1), one range of diploidy (white
box, gene CN score between 0.1 and 0.1) and two ranges of gain (red boxes, gene CN score >0.1). (D) Chromosome box plot for chromosome 3:
distribution of GE scores according to gene CN scores on all the SODEGIRs of a specific chromosome (e.g. chromosome 3).
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gene transcriptional activity is quantitatively correlated to
the gene dosage. Indeed, as shown in Figure 2C and D, the
CN and expression levels of genes sharing the same status
are tightly related both considering the whole-genome or a
single chromosome. Similar results have been obtained
when Caki-1 DNA was profiled using a Human
Mapping 250K Nsp array (Table 1 and Caki250k in
CWS).
The application of the entire procedure to astro-
cytoma and renal carcinoma data allowed determining
SODEGIRs for single samples and the definition of data-
set SODEGIR signatures. In particular, the analysis of
Astro samples highlighted CN regions spanning from
100 to 460Mb and affecting from 3% to 15% of the
human genome. GE regions spanned from 40 to 430Mb
and accounted from 1% to 14% of the genome (Table 1).
SODEGIRs are distributed over few chromosomes (from
1 to 3 chromosomes) and span from few Mb up to a max-
imum of 270Mb (sample HT1344, for detailed results see
CWS). Most samples present broad deleted or amplified
SODEGIRs on chromosomes 10 and 7, respectively (as
exemplified in Figure 3A by sample HT1139), and these
regions determine the strong correlation between gene
CN and transcriptional activity at the whole genome
level (Figure 3B). Similarly, CN regions ranging from
180 to 540Mb and GE regions covering from 50 to
580Mb were determined in RCCp samples (Table 1).
Again, SODEGIRs are distributed over few chromosomes
(from 1 to 5 chromosomes) and span from 14 (sample
40RR) to 290Mb (sample 28RA). Deleted and amplified
SODEGIRs are mostly localized on chromosomes 3 and
5, respectively (e.g. samples 50PC; Figure 4A) and genes
contained in these regions are characterized by correlated
levels of gene dosage and expression (Figure 4B).
A deeper analysis of SODEGIRs identified in the chro-
mosomes of the various tumor samples (Caki-1, Astro and
RCCp) allows defining four main chromosomal patterns
(Figure 5):
(i) Deletion of an entire chromosome characterized by
the combination of complete CN loss, LOH and GE
down-regulation (Figure 5A);
(ii) Deletion of part of a chromosome affected by CN
loss and GE down-regulation in absence of LOH
(Figure 5B);
(iii) Amplification of an entire chromosome character-
ized by the combination of complete CN gain and
GE up-regulation (Figure 5C);
(iv) Amplification of part of a chromosome affected by
CN gain and GE up-regulation (Figure 5D).
As reported in the analysis of Caki-1, amplified
SODEGIRs are not usually associated to LOH.
However, its worthwhile noting that, although the GE
status is normally associated to the CN one, there are
chromosomal area where the CN gain does not impact
the transcriptional activity (Figure 5C; q11.21–q21.3) or
vice versa, the GE up-regulation is not associated to a
corresponding CN gain (Figure 5D; p12–q23.1).
The aggregation of the single sample SODEGIRs
allowed identifying unique SODEGIR signatures for the
astrocytoma and renal carcinoma datasets. The Astro
signature is composed by three amplified regions distrib-
uted along chromosome 7, containing genes such as
EGFR, CAV1, MET and NOS3, and by two major
deleted regions on chromosome 10, containing GATA3
and PTEN tumor suppressors (Figure 6, Table 2).
Noticeably, a recurrent amplified block comprising
7q22.3–q31.2 is shared by nine patients and three patients
are characterized by a common deleted SODEGIR on
chromosome 10, spanning from q22.1 to the telomer.
Moreover, patients can be grouped according to their
SODEGIR pattern into those presenting both deletion
Figure 3. Visualization of SODEGIR results for the analysis of an Astro single sample (e.g. HT1139). (A) genome view and (B) genome box plot.
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and amplification (3 samples), those having only the
amplification (6 patients) and those without any
SODEGIR (3 patients). Similarly, the RCC signature is
composed of an amplified region on chromosome 5 and
a deleted one on chromosome 3 (Figure 7, Table 2). The
amplified SODEGIR, located at 5q21.3–q35.3 and shared
by eight samples, contains APC and PDGFB oncogenes
while the deleted SODEGIR (on 3p14.1–p22.3 in eleven
samples) hosts the well-known FHIT fragile site and
RASSF1 tumor suppressor gene.
DISCUSSION
The integration of multiple sources of information repre-
sents a promising approach to deepen the resolution and
Figure 5. Chromosome views. (A) and (B) show deleted SODEGIR on chromosome 10 of an Astro sample (e.g. HT1139) and on chromosome 3 of
an RCCp sample (i.e. 50PC); (C) and (D) report amplified SODEGIR for chromosomes 7 and 5 of an Astro (HT1139) and an RCCp (50PC) sample,
respectively.
Figure 4. Visualization of SODEGIR results for the analysis of an RCCp single sample (e.g. 50PC). (A) Genome view and (B) genome box plot.
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Figure 6. Results of the aggregation of SODEGIRs in the analysis of the Astro dataset. (A) q_plot: The statistical significance for the aggregation
of amplifications/deletions is displayed as q-value. Chromosome positions are indicated along the y-axis with the centromere positions identified
by yellow dotted lines. Amplifications (red lines) and deletions (green lines) that are shared by a statistically relevant number of samples surpass
the significance threshold (blue dotted line, q-value 0.05). (B) SDG chromosome view for chromosome 10 in all astrocytoma samples.
(C) SDG chromosome view for chromosome 7 in all astrocytoma samples.
Table 2. Summary of the SODEGIR signatures for the astrocytoma and renal carcinoma datasets
Chr Cytoband Start (Mb) End (Mb) Length (Mb) No of genes Relevant cancer genes
Astro dataset
Amplification signature
7 p22.1–q11.22 4.7 70.9 66.2 244 EGFR, IL6, RAC1, SFRP4, IGFBP3, PMS2
q21.13–q35 89.6 144.0 54.4 344 CDK6, MA7, CAV2, CAV1, CASP2, FLNC, WNT16,
WNT2, MET, PIK3CG, PON1
q36.1-q36.1 149.0 151.0 2.0 32 NOS3, CHK5, ABP1, RHEB
Deletion signature
10 10p15.1–10p12.2 4.9 23.6 18.8 82 GATA3, IL2RA, IL15RA, STAM, CACNB2, MLLT10
10q21.3–10q26.3 70.2 132.0 61.8 387 FRAT1, CASP7, CHUK, SAR1A, FAS, PTEN, BTRC,
HK1, MMP21, CYP2C9, MGMT, SUFU, DBMT1,
LGI1, MXI1
RCCp dataset
Amplification signature
5 5q21.1–5q21.2 99.9 103.0 3.1 9 —
5q21.3–5q35.3 108.0 179.0 71.0 419 IL9, IL4, IL5, GM-CS, IL13, MCC, NPM1, FGFR4,
SPINK1, APC, IRF1, ACSL6, CXCL14, PDGFB
Deletion signature
3 3p22.3–3p14.1 35.7 65.3 29.6 279 FHIT, MLH1, RASSF1, GPX1, ARMET, CCR3,
CCR2, CXCR6, CCR1, SAMA3F, PLXNB1, RHOA,
SMARCC1, TLR9
Amplified and deleted SODEGIRs are described in terms of cytoband, chromosomal region, and total number of annotated genes. Values have
been derived from .SDGset_Table files of datasets, as deposited in CWS.
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enhance the interpretation of gene dosage and expression
profiles alone. This strategy can be generalized to identify
and prioritize targets for functional studies which are
expected to hasten the translation of basic research find-
ings into clinical applications. The proof of principle of
this approach comes from the study by Garraway et al.,
who, combining genome-wide, SNP-based CN maps and
GE profiles, identified an amplified area containing the
transcription factor MITF, a novel, potential tissue-speci-
fic oncogene (13,25). However, an efficient integration of
GE profiling data with structural information requires
appropriate datasets, i.e. paired GE and CN signals for
the same sample and the development of computational
approaches to overcome the limits of simple correlation.
Although the number of studies combining CN and GE
measurements has been constantly increasing since the
development of high-throughput technologies (aCGH
and SNP mapping arrays), still the availability of paired
data sets with GE and CN from the same patient is lim-
ited. Moreover, the use of genomic and transcriptional
arrays from the same manufacturer, in which probes are
linked to precise chromosomal positions and are anno-
tated in the same format, is crucial for the implementation
of integrative methods. From a bioinformatics standpoint,
the integration of CN and GE levels is mostly achieved
using linear regression models and correlation coefficients
between DNA CN and mRNA expression (5–12). Given
the complex genomic environment of a tumor cell, this
approach may result inefficient in capturing wide-range
relationships between CN imbalances and GE changes.
Instead of focusing on the local correlation between the
two types of data, we developed a computational frame-
work which directly integrates CN and GE profiles at
genome-wide level, by statistically assessing the gene
dosage and transcription statuses on common genomic
positions. When applied to DNA/RNA paired data, this
procedure allows the identification of SODEGIRs and the
definition of tissue-specific SODEGIR signatures.
The method is based on estimating both CN and GE
scores at the same chromosomal coordinate, e.g. the
Entrez Gene physical position of a gene in base pairs.
In general, CN data can be obtained from aCGH or
Figure 7. Results of the aggregation of SODEGIRs in the analysis of the RCCp dataset. (A) q_plot: The statistical significance for the aggregation of
amplifications/deletions is displayed as q-value. Chromosome positions are indicated along the y-axis with the centromere positions identified by
yellow dotted lines. Amplifications (red lines) and deletions (green lines) that are shared by a statistically relevant number of samples surpass the
significance threshold (blue dotted line, q-value0.05). (B) SDG chromosome view for chromosome 5 in all RCCp samples. (C) SDG chromosome
view for chromosome 3 in all RCCp samples.
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SNP microarrays using methods based on Hidden
Markov Models or segmentation algorithms (18,26–32).
When using aCGH technology, genes are directly interro-
gated by specific gene probes and therefore the gene CN is
readily available for the same entity interrogated by the
expression array. Instead, using SNP mapping arrays, the
CN value refers to a SNP marker and the gene CN must
be estimated. To date, only two computational proce-
dures, i.e. dChip and FASeg, have been developed to cal-
culate the gene CN directly from SNP mapping data (33).
dChip infers the gene CN value by averaging the signals of
the SNP probes annotated in the chromosomal region
of the gene (31), while the fragment reduction algorithm
of FASeg produces fitted-CN data which can be anno-
tated at gene level (19). Differently from both dChip and
FASeg, the SODEGIR approach uses a kernel regression
estimator with automatically adapted local plug-in band-
width to estimate both CN and GE at the same gene phys-
ical position from signals of SNP and transcripts probes.
The estimation process is a non-parametric regression
where the signal, acquired by a probe designed to interro-
gate a given chromosomal position, is estimated at
another chromosomal coordinate using a smoothing func-
tion. Specifically, when estimating the regression function,
lokerns transforms CN and GE values of 115 561 SNP and
41 192 expression probes, respectively, into CN and GE
levels for 16 395 annotated Entrez genes through a local
averaging of the observations. A major advantage of this
kernel regression estimator is the possibility to automati-
cally adapt the smoothing bandwidth to account for the
non-uniform distribution and density of genes along the
genome. As such, the method automatically set the opti-
mal bandwidth according to the underlying structure of
the genome thus avoiding both too small bandwidths,
which would lead to wiggly regression curves and noisy
estimations, and too large ones, which could smooth away
important details (i.e. CN spikes or small local variations).
The efficacy of the locally adaptive approach in estimating
GE levels has been already shown in ref. (14), while its
application to the CN signals (LSCN) allows detecting
broad as well as subtle changes in gene CN. It is worth-
while noting that the lokerns function efficiently regresses
the CN data irrespectively of the array density (50K,
100K and 250K sets), although denser arrays allow a
finer smoothing of the data. To further assess the perfor-
mances of the LSCN part of the SODEGIR approach and
to verify if gene CN inferences and statistical scores intro-
duce any systematic error, gene CN status was quantified
using both LSCN and FASeg on the normal samples com-
posing the AffyRef dataset. Specifically, CN data for the
AffyRef samples were quantified by CNAT 4.01 algorithm
without any smoothing and loaded into LSCN and
FASeg. FASeg returned a matrix with CN data for all
SNP probes in all samples which was used to calculate
the gene CN values for 24 535 gene accession numbers.
After re-annotating gene accession numbers in terms of
Entrez Gene IDs and filtering out duplicate identifiers,
the FASeg gene CN matrix resulted in 15 702 Entrez
Gene IDs, all represented in the LSCN gene CN matrix.
As in LSCN, the CN status of a gene g in a sample j has
been defined setting a low and a high threshold on the
FASeg gene CN. Once determined the CN status of all
genes in all samples, a binomial distribution test with the
q-value correction has been applied to identify regions
of concordant status in a statistically relevant number of
samples. As expected given the genomic diploidy of
AffyRef normal samples, neither LSCN nor FASeg iden-
tified any region characterized by statistically relevant
gain/loss events. Moreover, the LSCN performed similarly
in estimating the gene CN starting from both CNAT
or CNAG data (see the AffyRef directory at CWS and
Supplementary Data). Thus, the quantification of the
CN score as defined by Equation (1) and the inference
of the gene CN status through the lokerns function repre-
sent a robust alternative to segmentation methods, when
performing a CN analysis alone. When DNA/RNA paired
signals are available, LSCN directly integrates with LAP
and the combined application of the two methods offers
the unique possibility to simultaneously access the CN and
GE status of any single gene. LSCN and LAP, as well as
the two together, perform the analysis both on single sam-
ples as well as at the level of an entire dataset, defining
sample-specific or tissue-specific genomic signatures.
In the latter case, the approach resembles what the
Multiple Sample Analysis (34) algorithm does on the
CN data, i.e. statistically merging CN and GE informa-
tion of single samples to increase the resolution of the
analysis. When applied to the analysis of astrocytoma
and renal carcinoma DNA/RNA paired data, the
SODEGIR procedure identified unique SODEGIR signa-
tures which are in complete agreement with the genomic
imbalances recently described for these two tumors
(35,36). Specifically, the three amplified regions on chro-
mosome 7 and the two major deleted regions on chromo-
some 10 composing the Astro SODEGIR signature are
overlapping with the broad events detected by Genomic
Identification of Significant Targets in Cancer [GISTIC,
(35)] in gliomas. In ref. (35), broad events including
amplifications of chromosome 7 and deletions of chromo-
some 10, are observed in more than 80% of the tumor
specimens and contain the same amplified (EGFR,
CAV1, MET, NOS3) and deleted genes (GATA3 and
PTEN) identified by the SODEGIR approach (Figure 6,
Table 2). In addition, the SODEGIR signature allowed
grouping patients according to their chromosomal aberra-
tion pattern (i.e. samples affected by both deletion and
amplification, only amplification or no aberration) which
may define histopathological subgroups. The SODEGIR
signature of clear cell renal carcinoma is composed of
an amplified region located at 5q21.3–q35.3 and a deleted
one at 3p14.1–p22.3, containing the APC oncogene and
the FHIT fragile site, respectively (Figure 7, Table 2).
Similarly, Yoshimoto and colleagues detected gains of
chromosome 5q33.1-qter and losses of 3p25.1–p25.3 and
3p21.31–p22.3 in 58% and 80%, respectively, of the 30
renal cell carcinomas analyzed using aCGH (36).
Moreover, they found that significantly more up-regulated
genes were localized on chromosome 5 and that, conver-
sely, significantly more down-regulated genes were loca-
lized on chromosome 3. The SODEGIR integrative
analysis allowed to quantitatively assessing the impact of
gene dosage on gene transcriptional activity, both at the
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whole-genome and at the chromosome levels. In accor-
dance with (6), CN gain seems to have a stronger influence
on regional transcriptional activity than CN loss. The
fact that gene amplification greatly enhances GE while
there are many aneuploidy-independent mechanisms lead-
ing to down-modulation of transcriptional activity
(Figures 2C and D, 3B, and 4B) is supported by several
evidences from mammalian cell lines and tumors (37,38)
and should be taken into consideration when chromo-
somal instability is inferred from transcriptional profiles.
The SODEGIR approach is robust both with respect to
the algorithm used to generate CN data and to the exper-
imental design. Specifically, using the renal carcinoma
dataset, the performance of LSCN was evaluated on CN
values generated by CNAT and CNAG using paired
normal specimens (i.e. the matched blood samples of the
tumor tissues, RCCp) and HapMap samples as the refer-
ence set (RCC). LSCN performed similarly irrespectively
of the type of method used to generate the CN and of the
type of experimental scheme. However, LOH likelihood
calculation was more efficient using matched normal sam-
ples as reference (data not shown).
In conclusion, SODEGIR represents a bioinformatics
procedure for the integrative, gene-position based analysis
of CN and GE data that allows the identification of dis-
crete chromosomal regions of coordinated DNA CN
alterations and changes in transcriptional levels. These
imbalanced regions may constitute a valuable resource
for discovering novel diagnostic, prognostic, and thera-
peutic markers, although deciphering the mechanisms
of transcriptional regulation of genes associated with
chromosomal aberrations will likely require the inte-
gration of additional information (e.g. microRNA expres-
sion levels, fluorescence in situ hybridization, mutations,
methylation, chromatin immunoprecipitation, post-
transcriptional regulation) and the development of statis-
tical approaches able to handle different types of genomic
data (39).
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